BridgeMD
A multicentre, open-label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens when administering a single-dose, intramuscular vaccination as simulated post-exposure prophylaxis at least five years following priming.
EU CTIS ID: 2025-524765-24-00
What this study is testing
To investigate whether the boostability of a (A) two-visit Intra-muscular, (B) two-visit Intra-dermal and (C) one-visit Intradermal vaccination regimen is non-inferior to a theoretical 99% boostability when a single-dose Intramuscular vaccination is administered at least 5 years after the PrEP regimen.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 and ≤ 60 years at the time of inclusion.
- Willing and able to provide written informed consent.
- Having received rabies Rabies vaccination through a 2x1 IM, 2²ID, or 1²ID regimen at least 5 years prior to study start.
You likely can't join if
- Subjects with a known allergy to one of the components of the vaccines
- Currently receiving or having received immunomodulating drugs within the past 3 months (12 weeks).
- Planned vaccination with any inactivated vaccine within 2 weeks before or after the vaccinations in the study or with any live attenuated vaccine within 1 month before or after the vaccinations in the study.
- Ongoing pregnancy or active child wish (for female subjects) at the time of booster vaccination (D0).
- Any other PrEP rabies vaccination schedules than those mentioned in the inclusion criteria.
- Previous rabies booster vaccinations
See the full eligibility criteria
- Age ≥ 18 and ≤ 60 years at the time of inclusion.
- Willing and able to provide written informed consent.
- Having received rabies Rabies vaccination through a 2x1 IM, 2²ID, or 1²ID regimen at least 5 years prior to study start.
- Subjects with a known allergy to one of the components of the vaccines
- Currently receiving or having received immunomodulating drugs within the past 3 months (12 weeks).
- Planned vaccination with any inactivated vaccine within 2 weeks before or after the vaccinations in the study or with any live attenuated vaccine within 1 month before or after the vaccinations in the study.
- Ongoing pregnancy or active child wish (for female subjects) at the time of booster vaccination (D0).
- Any other PrEP rabies vaccination schedules than those mentioned in the inclusion criteria.
- Previous rabies booster vaccinations
- Inability or unwillingness to comply with study procedures,
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.